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Human immunodeficiency virus (HIV) is the causative agent of acquired immune deficiency syndrome (AIDS). Anti-
HIV agents targeting various steps in HIV life cycle have been developed; however, so far, no effective drugs have
been found. We show here that a peptide isolated from Spirulina maxima (SM-peptide) inhibits HIV-1 infection in a
human T cell line MT4. SM-peptide inhibited HIV-1IIIB-induced cell lysis with a half-maximal inhibitory concentration
(IC50) of 0.691 mM, while its 50 % cytotoxic concentration (CC50) was greater than 1.457 mM. Furthermore, the SM-
peptide inhibited the HIV-1 reverse transcriptase activity and p24 antigen production. This suggests that SM-peptide
is a novel candidate peptide, which may be developed as a therapeutic agent for acquired immunodeficiency
syndrome patients.
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Acquired immunodeficiency syndrome (AIDS) was first
reported in the USA in the year 1981. Since then, the
number of AIDS patients and HIV-infected persons are
persistently increasing worldwide. In 2015, the World
Health Organization (WHO) reported that there are
over 36.7 million AIDS patients worldwide (http://
www.who.int/hiv/en/). To solve the problems resulting
from AIDS, many investigations were conducted in
many countries. Some well-known AIDS therapeutic
agents such as 3′-azido-2′,3′-dideoxythymidine (AZT)
and 2′,3′-dideoxyinosine (ddI) were approved by the
Food and Drug Administration (FDA) and are now
being administered to AIDS patients (Broder, 2010).
However, these therapeutic agents are associated with
many side effects such as anemia, neutropenia, and
thrombocytopenia (Ay et al., 2013). Therefore, many
research groups are being required to search for novel
anti-HIV agents compatible to those of developed coun-
tries. Marine-based natural products that have chem-
ically diverse and unique structures have received
attention as sources for the development of new anti-
HIV agents (Vo and Kim, 2010). Marine materials such
as phlorotannins, sulfated chitoolifosaccharides, sulfated* Correspondence: parksj@pknu.ac.kr
Department of Chemistry, Pukyong National University, Busan 608-737,
Republic of Korea
© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zepolysaccharides, and lectin have been reported to have
anti-HIV activities. Additionally, several recent studies
have reported that peptides from marine organisms can
act as anti-HIV agents because of their therapeutic
potential in the treatment of infectious diseases (Plaza
et al., 2007 and 2009). In this regard, we examined anti-
HIV activities of our previously isolated peptides from
several marine organisms and found that a peptide from
Spirulina maxima (SM-peptide) inhibits HIV-1 infection
in human T cell line MT4. SM-peptide inhibited HIV-
1IIIB-induced cell lysis, p24 antigen production, and
HIV-1 reverse transcriptase.Methods
Materials and chemicals
We purified the S. maxima peptide as reported by Vo et al.
(2014). The purity of the peptide was >98 % according to
RP-HPLC assessment and N-terminal sequence analysis.
The amino acid sequence of the final purified peptide was
determined to be LDAVNR by electrospray ionization mass
spectrometry (ESI/MS) (Vo et al., 2014).
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) was purchased from Sigma–Aldrich
(St. Louis, USA). DMSO was obtained from Amresco
(Solon, USA). Specific antibodies for western blot were
purchased from R&D systems (NE Minneapolis, USA)
and Santa Cruz Biotechnology (Dallas, USA).le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 SM-peptide is noncytotoxic in MT4 cells. MT4 cells were
treated with 0–1 mg/ml SM-peptide for 72 h, and the viability of
MT4 cells was measured by MTT assay. The data shown in the figure
represents an average of three independent experiments. All data
are presented as mean ± S.D
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MT4 and H9/HIV-1IIIB cell lines were obtained from the
NIH AIDS Reagent Program (Germantown, USA). All
cell lines were cultured in RPMI-1640 (Thermo Scien-
tific, USA) supplemented with 10% heat-inactivated FBS
(Thermo Scientific, USA), 50 μg of streptomycin, and
50 U of penicillin per milliliter (PAA, USA) in 5 % CO2
containing air at 37 °C. Cells were passaged every 2–
4 days and maintained at a cell density of 5 × 105–1 ×
106 cells/ml. HIV-1IIIB viral particles were obtained from
the supernatants of H9/HIV-1IIIB cell line. The viruses
were stored at −80 °C until use. Viral titer was deter-
mined by p24 assay performed using MT4 cells. Viral
titer was expressed as TCID50.
Cell viability assay
MT4 cells were seeded in a 96-well plate at 2 × 104 cells/
well with RPMI-1640 medium containing 10 % FBS.
After 24 h, the cells were treated with SM-peptide and
incubated further for 24 h at 37 °C. Twenty-four hours
later, fresh RPMI-1640 medium with 10 % FBS was
added to each well. After 84 h, 20 μl of MTT solution
(final concentration of 0.5 mg/ml) was added to each
well and the plate was incubated for 4 h at 37 °C. Finally,
200 μl of DMSO was added to dissolve the purple
formazan. The amount of formazan was determined by
measuring absorbance at 595 nm using a microplate
reader (Filter Max 5, Molecular Devices).
Cell lysis effect by HIV-1IIIB infection
To determine the anti-HIV activity of SM-peptide on
HIV-infected MT4 cells, MTT assay was performed.
MT4 cells were seeded in duplicate in a 96-well plate at
a density of 2 × 104 cells/well. After 24 h, stock virus of
HIV-1IIIB was added to each well at 50 TCID50 along
with the different concentrations of SM-peptide. The
plate was incubated for 72 h at 37 °C with 5 % CO2. Cell
viability was determined by MTT assay.
p24 antigen production assay
MT4 cells (2 × 104 cells/well) were seeded in a plate.
After 1 day, the MT4 cells were treated with SM-peptide
and infected with 50 TCID50 of HIV-1IIIB. The plate was
incubated for 72 h. The supernatant was harvested by
centrifugation. In order to determine the amount of
HIV, Lenti-X p24 rapid titer kit was used according to
the manufacturer’s protocol (Clontech, USA).
Reverse transcriptase activity assay
The activity of HIV-1 reverse transcriptase in the
virus supernatant was determined by using a reverse
transcriptase assay kit (Roche, Germany) according to
the manufacturer’s protocol. Briefly, a reaction mix-
ture containing poly(A) × oligo(dT)15 was added tothe virus supernatant and incubated for 4 h at 37 °C.
Two hundred microliters of anti-DIG-POD and ABTS
were then added stepwise. The virus supernatant was
incubated at room temperature until the color devel-
opment was sufficient for detection. The absorbance
of the virus supernatant was measured using a micro-
plate reader at 405 nm.
Statistical analysis
Data were analyzed using the InStat statistics program
(GraphPad Software, Inc., San Diego, CA, USA). Statistical
comparisons were performed using one-way analysis of
variance (ANOVA) with Duncan’s multiple comparisons
test. Differences were considered significant at p < 0.05.
Results
To identify natural peptides with anti-HIV-1 activity, we
screened peptides from several marine organisms for
their anti-HIV-1 activities. In this study, we showed that
a peptide isolated from S. maxima, SM-peptide, has an
anti-HIV-1 activity. The peptide was previously purified
from enzymatic hydrolysates of S. maxima, and its
sequence is LDAVNR with molecular mass of 686.37 Da
(Vo et al., 2014).
We first examined the cytotoxicity of SM-peptide in
human MT4 T cells. The MT4 cells were treated with
0–1 mg/ml SM-peptide for 72 h, and the viability of
MT4 cells was measured by a formazan-based MTT
assay. Figure 1 shows that the SM-peptide did not affect
the viability of MT4 cells at concentrations below 1 mg/
ml (1.457 mM). Next, the protective activity of the SM-
peptide on HIV-1IIIB-induced cell lysis was also investi-
gated by MTT assay (Fig. 2). HIV-1IIIB-induced lysis of
Fig. 2 SM-peptide inhibits HIV-1IIIB-induced MT4 cell lysis. MT4 cells
were infected with HIV-1IIIB at 50 TCID50 in the presence or absence
of 0–1 mg/ml SM-peptide. After 72 h, the inhibitory effect of SM-
peptide was determined using MTT assay. Inhibition of cell lysis was
expressed as cell lysis level compared to that in HIV-1IIIB-infected
control cells without SM-peptide. The data shown in the figure
represents an average of at least three independent experiments.
The IC50 values were determined by analyzing the data with GraphPad
Prism 7.0. The X-axis in the graph is presented as log10 values
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peptide against anti-HIV-1IIIB infection was assessed to
be 0.475 mg/ml (0.691 mM).
The anti-HIV-1 activity of SM-peptide was further
examined by determining its effect on HIV-1 reverse tran-
scriptase (RT) activity. RT activity is used by the HIV-1
retrovirus to convert single-strand genomic RNA into
double-strand cDNA which can integrate into the host
genome, potentially generating a long-term infection. SM-
peptide was found to inhibit HIV-1IIIB-induced RT activa-
tion in MT4 cells (Fig. 3). SM-peptide (0.75 mg/ml,Fig. 3 SM-peptide inhibits HIV-1 reverse transcriptase activity. The effect
of SM-peptide on HIV-1 reverse transcriptase activity was determined by
colorimetric RT activity assay. The data shown in the figure represents
an average of at least three independent experiments. The IC50 values
were determined by analyzing the data with GraphPad Prism 7.0. The
X-axis in the graph is presented as log10 values1.093 mM) inhibited the RT activity in HIV-1IIIB-infected
cells by approximately 90 % as compared to control (no
peptide). In addition, we examined the effect of SM-
peptide on HIV-1 p24 antigen production. p24 antigen is
a structural protein that makes up most of the HIV viral
core. High levels of p24 are present in the blood serum of
newly infected individuals during the short period be-
tween infection and seroconversion, making p24 antigen
assays useful in diagnosing primary HIV infection. As
shown in Fig. 4, SM-peptide (0.75 mg/ml, 1.093 mM)
inhibited the HIV-1IIIB p24 antigen production by more
than 95 %. The inhibitory effect of SM-peptide on p24
protein production was also confirmed by western blot
analysis of cell lysates with anti-p24 antibody. SM-peptide
treatment decreased the HIV-1 p24 production signifi-
cantly in cell lysates.
Taken together, these results suggest that marine nat-
ural SM-peptide inhibits HIV-1 infection by suppressing
HIV-1IIIB-induced cell lysis, HIV-1 reverse transcriptase
activity, and p24 antigen production.
Discussion
HIV, the causative agent of AIDS, is one of the hottest
areas of medical research today. Because of the high
prevalence and mortality associated with HIV infections,
many researchers have focused on finding ways to fight
the infection and improve the life span of HIV-infected
individuals. So far, there are five major classes of anti-
HIV-1 drugs that targeted distinct steps in the HIV life
cycle: reverse transcriptase inhibitors, protease inhibi-
tors, fusion inhibitors, integrase inhibitors, and multi-
drug combinations (Lifson et al., 2016). These drugs,
though effective, do not cure HIV/AIDS. People with
HIV infection still have the virus in their bodies and can
spread the virus to others. Therefore, to improve the
therapeutic potential of these medicines, identification of
additional and suitably modified novel drug candidates is
necessary (Migueles and Connors, 2015).
Numerous recent studies have reported that marine
peptides from marine sponges may be used as anti-HIV
agents (Vo and Kim, 2010; Ngo et al., 2012). The marine
peptides have been found to mainly inhibit viral entry
through membrane fusion (Plaza et al., 2007 and 2009;
Zampella et al., 2008; Oku et al., 2004). The present
study showed that a peptide isolated from S. maxima
(SM-peptide) is noncytotoxic and inhibits HIV-1IIIB-in-
duced cell lysis, reverse transcriptase activity, and viral
p24 antigen production. SM-peptide was isolated and
reported to downregulate the IgE receptor-mediated
mast cell activation by Vo et al. (2014). HIV-induced im-
mune dysfunction has been known to increase the likeli-
hood of developing allergic and other immune-mediated
diseases in patients. Antiretroviral therapy is associated
with reconstitution of the immune system function.
Fig. 4 SM-peptide inhibits HIV-1IIIB-induced p24 antigen production. MT4 cells were infected with HIV-1IIIB of 50 TCID50 in the presence or absence
of 0–1 mg/ml SM-peptide. The amount of p24 production was determined by p24 antigen capture ELISA. The data shown in the figure represents
an average of at least three independent experiments. The IC50 values were determined by analyzing the data with GraphPad Prism 7.0. The X-axis
in the graph is presented as log10 values. Cellular p24 proteins were also analyzed by western blot analysis. MT4 cells were infected with HIV-1IIIB
of 50 TCID50 in the presence or absence of 1 mg/ml SM-peptide
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body’s defense mechanism against infectious immune
system disorder.
We tried to generate several derivatives of synthetic
peptide to identify the specific amino acid residues
responsible for the anti-HIV-1 activity of SM-peptide;
however, we were unable to perform experiments in cells
because of the insolubility of the synthetic peptides.
Thus, the simulation methods such as the molecular
docking approach may be useful to determine the mech-
anism of SM-peptide action on HIV-1 infection. In
conclusion, SM-peptide is a novel and safe peptide with
HIV-1 inhibitory activity and may be a promising candi-
date for the design of novel HIV/AIDS drugs.Conclusions
We demonstrated that a peptide from S. maxima in-
hibits HIV-1 infection in a human T cell line MT4. SM-
peptide exhibits inhibitory activity on HIV-1IIIB-induced
lysis, p24 antigen production, and HIV-1 reverse tran-
scriptase at noncytotoxic concentrations. This finding
suggests that the marine peptide SM-peptide is a novel
candidate peptide, which may be developed as a thera-
peutic agent for AIDS patients.
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